Immunotherapies for Immune-Mediated myopathies: A current perspective

Needham, M. and Mastaglia, F.L. (2015) Immunotherapies for Immune-Mediated myopathies: A current perspective. Neurotherapeutics, 13 (1). pp. 132-146.

Abstract

Until recently, the treatment of immune-mediated inflammatory myopathies has largely been empirical with glucocorticoids, steroid-sparing immunosuppressive drugs, and intravenous immunoglobulin. However, a proportion of patients are only partially responsive to these therapies, and there has been a need to consider alternative treatment approaches. In particular, patients with inclusion body myositis are resistant to conventional immunotherapies or show only a transient response, and remain a major challenge. With increasing recognition of the different subtypes of immune-mediated inflammatory myopathies, and improved understanding of their pathogenesis, more targeted treatments are now being trialled. The overall approach to treatment, and novel therapies targeting B cells, T cells, and specific cytokines are discussed in this review.

Item Type:	Journal Article
Murdoch Affiliation:	Institute for Immunology and Infectious Diseases
Journal or Publication Title:	Neurotherapeutics
Page Range:	pp. 132-146
Publisher:	Springer US
URI:	http://researchrepository.murdoch.edu.au/id/eprint/29152

Item Control Page